Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Implementation of Seizure and Status Epilepticus Protocols in the Emergency Department of a large Academic Hospital
Epilepsy/Clinical Neurophysiology (EEG)
P2 - Poster Session 2 (5:30 PM-6:30 PM)
6-023
Access to healthcare is a prominent issue in the US. This provides for patients utilizing EDs for primary care and outpatient needs. The UHS ED, Neurology department, and system faces the dilemma of caring for a large population of patients which has led to prioritization and optimization of efficiency and throughput. Here, we will look at patients who present in active seizure and those who present after a seizure event.
An enormous amount of research has investigated treatments for new onset seizure as well as status epilepticus (SE).  In fact, a large trial investigating SE medication choices is currently underway.  This study allows for a dosing guideline identified to assist in process and choice of AED. 

We have created and will implement two protocols; SE as well as an overall approach to the seizure patient, with hopes to optimize the processes for both.

 

We will review all seizure patients within last 2 years seen in the UHS ED. Separate de-identified patient cases into first time seizure, known epilepsy, or SE from either group.

Preliminary Historical Data from '16-'17 on all patients seen with any level of service seen in ED of UH with primary concern for seizure.  A total of 865 patients were seen with these parameters with an average LOS of 1.68.  Of these, 616 were discharged from ED, and this subset had an average LOS of 1.05.  

Data to be analyzed after implementation of pathway for close PCP follow up, avoidance of unnecessary hospitalizations/level of care, and reduce  patients lost to follow up, and reduce repeat ED visits for same diagnosis.  Protocols went into effect Oct 1, and this study will reflect the initial 4 months of protocol use.  

 
Authors/Disclosures
Kyna Schreiber, MD (UT Health Center Tyler)
PRESENTER 		Dr. Schreiber has received research support from NIH.